TY - JOUR
T1 - Role of interferon in melanoma
T2 - old hopes and new perspectives
AU - Sanlorenzo, Martina
AU - Vujic, Igor
AU - Carnevale-Schianca, Fabrizio
AU - Quaglino, Pietro
AU - Gammaitoni, Loretta
AU - Fierro, Maria Teresa
AU - Aglietta, Massimo
AU - Sangiolo, Dario
PY - 2017/4/3
Y1 - 2017/4/3
N2 - Introduction: Interferons (IFNs) play a key role in modulating anti-microbial and antitumor immune responses. In oncology, past attempts to exploit IFNs therapeutically did not fulfill expectations, and had only modest clinical results, mostly limited to adjuvant melanoma treatment. The recent successes of immunotherapy in oncology have brought new attention to the potential of immune-modulatory agents like the IFNs. Areas covered: The authors review the biological effects of IFN on melanoma and immune cells. Then, the authors summarize the clinical results of adjuvant and therapeutic IFN in melanoma, giving focus to possible prognostic factors and new on-going clinical trials. Expert opinion: IFNs offer intriguing opportunities for synergism between conventional treatments and recently introduced molecular-targeted and immunotherapy approaches. However, the full comprehension of all IFN effects and their multiple biologic links is challenging. A strong commitment toward parallel translational research is needed to facilitate the interpretation of IFN’s expected and unexpected effects, guiding the rational design of informative clinical studies.
AB - Introduction: Interferons (IFNs) play a key role in modulating anti-microbial and antitumor immune responses. In oncology, past attempts to exploit IFNs therapeutically did not fulfill expectations, and had only modest clinical results, mostly limited to adjuvant melanoma treatment. The recent successes of immunotherapy in oncology have brought new attention to the potential of immune-modulatory agents like the IFNs. Areas covered: The authors review the biological effects of IFN on melanoma and immune cells. Then, the authors summarize the clinical results of adjuvant and therapeutic IFN in melanoma, giving focus to possible prognostic factors and new on-going clinical trials. Expert opinion: IFNs offer intriguing opportunities for synergism between conventional treatments and recently introduced molecular-targeted and immunotherapy approaches. However, the full comprehension of all IFN effects and their multiple biologic links is challenging. A strong commitment toward parallel translational research is needed to facilitate the interpretation of IFN’s expected and unexpected effects, guiding the rational design of informative clinical studies.
KW - immunotherapy
KW - Interferon
KW - melanoma
UR - http://www.scopus.com/inward/record.url?scp=85014820993&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014820993&partnerID=8YFLogxK
U2 - 10.1080/14712598.2017.1289169
DO - 10.1080/14712598.2017.1289169
M3 - Review article
C2 - 28274138
AN - SCOPUS:85014820993
VL - 17
SP - 475
EP - 483
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 4
ER -